Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 42.88B | 42.86B | 44.91B | 39.21B | 32.22B |
Gross Profit | 17.70B | 17.11B | 19.50B | 20.23B | 16.50B |
EBITDA | 11.80B | 11.08B | 11.94B | 12.96B | 10.19B |
Net Income | 6.33B | 6.00B | 6.95B | 7.72B | 6.38B |
Balance Sheet | |||||
Total Assets | 97.32B | 98.73B | 97.15B | 95.12B | 69.05B |
Cash, Cash Equivalents and Short-Term Investments | 5.57B | 8.08B | 8.52B | 4.48B | 10.32B |
Total Debt | 31.27B | 34.92B | 34.49B | 34.87B | 21.73B |
Total Liabilities | 47.65B | 51.88B | 53.01B | 54.15B | 34.53B |
Stockholders Equity | 49.55B | 46.73B | 43.98B | 40.79B | 34.51B |
Cash Flow | |||||
Free Cash Flow | 7.27B | 6.93B | 6.91B | 7.02B | 6.82B |
Operating Cash Flow | 8.67B | 8.41B | 9.15B | 9.54B | 8.29B |
Investing Cash Flow | -5.84B | -5.14B | -2.16B | -21.93B | -1.51B |
Financing Cash Flow | -6.79B | -3.62B | -2.81B | 6.58B | 959.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | $44.23B | 50.82 | 59.33% | ― | 5.56% | 4.66% | |
77 Outperform | $176.18B | 27.01 | 13.46% | 0.35% | 2.05% | 7.03% | |
75 Outperform | $34.19B | 29.47 | 18.88% | 0.82% | 0.56% | -4.08% | |
72 Outperform | $34.14B | 29.09 | 19.80% | ― | 3.53% | -10.72% | |
71 Outperform | $17.77B | 27.07 | 40.82% | ― | 2.57% | 8.31% | |
68 Neutral | $141.70B | 42.03 | 6.68% | 0.58% | -3.24% | -16.60% | |
60 Neutral | HK$17.07B | 6.10 | -7.44% | 2.88% | 11.55% | -28.15% |
On July 23, 2025, Thermo Fisher Scientific Inc. announced that its Senior Vice President and Chief Financial Officer, Stephen Williamson, will retire effective March 31, 2026. James R. Meyer, currently Vice President of Financial Operations, will succeed Williamson as CFO starting March 1, 2026, bringing extensive experience within the company since joining in 2009.
The most recent analyst rating on (TMO) stock is a Buy with a $680.00 price target. To see the full list of analyst forecasts on Thermo Fisher stock, see the TMO Stock Forecast page.
At the Annual Meeting on May 21, 2025, Thermo Fisher shareholders elected board nominees for a one-year term and ratified PricewaterhouseCoopers LLP as the independent auditor for 2025. However, a proposal on executive compensation was not approved, and a shareholder proposal to remove the one-year holding period for calling special meetings was also rejected.
The most recent analyst rating on (TMO) stock is a Buy with a $680.00 price target. To see the full list of analyst forecasts on Thermo Fisher stock, see the TMO Stock Forecast page.
On May 21, 2025, Thermo Fisher‘s Board of Directors approved a 5-year performance-based restricted stock unit award for CEO Marc N. Casper, aimed at securing his leadership until May 2030 and driving substantial shareholder returns. The award, valued at approximately $60 million, is designed to incentivize sustained shareholder value growth through total shareholder return outperformance, with payouts based on performance relative to the S&P 500 over a set period.
The most recent analyst rating on (TMO) stock is a Buy with a $680.00 price target. To see the full list of analyst forecasts on Thermo Fisher stock, see the TMO Stock Forecast page.